3 days Ago By By Nanoscope Therapeutics
DALLAS , Sept. 16, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy today announced presentations at the Euretina Innovation Spotlight and at Ophthalmology Futures Forum taking place on 18 th September in Barcelona, Spain .
Details for the presentations are as follows: Title: Breakthrough in Vision Restoration: Mutation-agnostic Optogenetics for Inherited Retinal Diseases and Geographic Atrophies Session Title: Nonneovascular AMD and IRDs Session Date: September 18, 2024 Session Time: 14:35 p.m. CEST Location: Barcelona International Convention Center Presenter: Samuel Barone, MD, Chief Medical Officer In his presentation followed by a panel discussion, Dr.
Barone will highlight the Multi-Characteristic Opsin (MCO) therapy pipelines of Nanoscope for the treatment of severe vision loss due to retinitis pigmentosa, Stargardt macular degeneration, and geographic atrophy. Title: Democratizing Gene Therapy for Retinal Degenerative Diseases Session Title: Company Presentations 3 Session Date: September 18, 2024 Session Time: 17:55 p.m.
CEST Location: Esferic Barcelona Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer During his presentation, Dr. Mohanty will highlight the mutation-agnostic optogenetic gene therapy for vision restoration in inherited retinal dystrophies, and geographic atrophy. He will also participate in a panel discussion, chaired by Prof.
Dominik Fischer , Professor at the University of Oxford . Panel Title: Gene & Cell Therapy Outlook for Back of the Eye Diseases: Is this Really a Business? Panel Date: September 18, 2024 Panel Time: 18:40 - 19:10 p.m.
CEST Location: Esferic Barcelona Panelist: Samarendra Mohanty, PhD, President & Chief Scientific Officer Both these events include networking opportunities with industry leaders, clinicians, innovators, regulators, and investors. The management team will be in attendance at these events and accessible for meetings. About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S.
for retinitis pigmentosa ( NCT04945772 ). The company has also completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients ( NCT05417126 ). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt.
Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy. Investor Contact: Argot Partners (212) 600-1902 [email protected] View original content to download multimedia: https://www.
prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-euretina-innovation-spotlight-and-ophthalmology-futures-forum-in-barcelona-302248567.html SOURCE Nanoscope Therapeutics.
